BiotechTube
Home/Curis/James Dentzer
JD

James Dentzer

President & CEO

Curis

Therapeutic Areas

OncologyHematologic Malignancies

Curis Pipeline

DrugIndicationPhase
Emavusertib (CA-4948)IRAK4-driven Leukemia (AML/MDS)Phase 1/2
FimepinostatMYC-altered Cancers (DLBCL, solid tumors)Phase 2
CA-170PDL1/VISTA-expressing CancersPhase 1
CA-327PDL1/TIM3-expressing CancersPreclinical

Leadership Team at Curis

DD
Diantha Duvall
Chief Financial Officer
AH
Ahmed Hamdy, MBBCH
Chief Medical Officer
RM
Robert Martell, M.D., Ph.D.
Chief Scientific Officer
JZ
Jonathan Zung, Ph.D.
Chief Development Officer
NS
Nancy Soohoo
Vice President & General Counsel
ME
Maureen E. Lane, Ph.D.
Vice President, Clinical and Translational Science
NP
Nick Pelletier, MBA
Vice President, Clinical Operations
LZ
Li Zhou, Ph.D.
Vice President, Biostatistics
MN
Mark Noel
Vice President, Technology Management & Intellectual Property
RB
Rachel Blasbalg
Senior Director, Human Resources
View full Curis profile